ArticlePLoS neglected tropical diseases2013
The potential elimination of Plasmodium vivax malaria by relapse treatment: insights from a transmission model and surveillance data from NW India.
Article in PLoS neglected tropical diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Mass Relapse Prevention to Reduce Transmission of Plasmodium vivax- A Systematic Review.The American journal of tropical medicine and hygiene · 2024Pooled it
- Superinfection and the hypnozoite reservoir for Plasmodium vivax: a multitype branching process approximation.Journal of mathematical biology · 2026Article
- Evaluating Natural Larvicides: Peppermint and Pepper Extracts versus Temephos onJournal of arthropod-borne diseases · 2025Article
- The probability of Plasmodium vivax acute illness following primary infection and relapse in Papua New Guinea.PLoS neglected tropical diseases · 2025Article
- Challenges to Malaria Elimination in Ethiopia by 2030: A Review.Journal of tropical medicine · 2025Review
- A hybrid transmission model for Plasmodium vivax accounting for superinfection, immunity and the hypnozoite reservoir.Journal of mathematical biology · 2024Article
- Possible potential spread of Anopheles stephensi, the Asian malaria vector.BMC infectious diseases · 2024Article
- Mathematical models of Plasmodium vivax transmission: A scoping review.PLoS computational biology · 2024Article
- Superinfection and the hypnozoite reservoir for Plasmodium vivax: a general framework.Journal of mathematical biology · 2023Article
- Time lag effect on malaria transmission dynamics in an Amazonian Colombian municipality and importance for early warning systems.Scientific reports · 2023Article
- Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders.Malaria journal · 2023Article
- Malaria, climate variability, and interventions: modelling transmission dynamics.Scientific reports · 2023Article
- Optimal Interruption of P. vivax Malaria Transmission Using Mass Drug Administration.Bulletin of mathematical biology · 2023Article
- A Multiscale Mathematical Model of Plasmodium Vivax Transmission.Bulletin of mathematical biology · 2022Article
- The neglected role of relative humidity in the interannual variability of urban malaria in Indian cities.Nature communications · 2022Article
- Using observed incidence to calibrate the transmission level of a mathematical model for Plasmodium vivax dynamics including case management and importation.Mathematical biosciences · 2022Article
- Malaria elimination on Hainan Island despite climate change.Communications medicine · 2022Article
- Malaria trends in Ethiopian highlands track the 2000 'slowdown' in global warming.Nature communications · 2021Article
- Basic Research ofFrontiers in cellular and infection microbiology · 2021Review
- Cost-Effectiveness Analysis of Sex-StratifiedThe American journal of tropical medicine and hygiene · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundWith over a hundred million annual infections and rising morbidity and mortality, Plasmodium vivax malaria remains largely a neglected disease. In particular, the dependence of this malaria species on relapses and the potential significance of the dormant stage as a therapeutic target, are poorly understood. METHODOLOGY/PRINCIPAL
findingsTo quantify relapse parameters and assess the population-wide consequences of anti-relapse treatment, we formulated a transmission model for P. vivax suitable for parameter inference with a recently developed statistical method based on routine surveillance data. A low-endemic region in NW India, whose strong seasonality demarcates the transmission season, provides an opportunity to apply this modeling approach. Our model gives maximum likelihood estimates of 7.1 months for the mean latency and 31% for the relapse rate, in close agreement with regression estimates and clinical evaluation studies in the area. With a baseline of prevailing treatment practices, the model predicts that an effective anti-relapse treatment of 65% of those infected would result in elimination within a decade, and that periodic mass treatment would dramatically reduce the burden of the disease in a few years. CONCLUSION/SIGNIFICANCE: The striking dependence of P. vivax on relapses for survival reinforces the urgency to develop more effective anti-relapse treatments to replace Primaquine (PQ), the only available drug for the last fifty years. Our methods can provide alternative and simple means to estimate latency times and relapse frequency using routine epidemiological data, and to evaluate the population-wide impact of relapse treatment in areas similar to our study area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.